Bispecific Antibody Market
Number of pages: 100 | Report Format: PDF | Published date: May 05, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
9.01% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Drug type, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global bispecific antibody market is expected to register a revenue CAGR of 9.01% during the forecast period from 2023 to 2031.
Bispecific Antibody Market Fundamentals
A bispecific antibody is an engineered antibody that can simultaneously bind to two different target molecules. It is a fusion protein combining two different antigen-binding sites, typically from two monoclonal antibodies, into a single molecule. This allows the bispecific antibody to bring different types of cells or molecules into proximity, which can result in various therapeutic effects. Bispecific antibodies can be designed to target a variety of different molecules, including cancer cells, immune cells, and inflammatory molecules. They can redirect immune cells to attack cancer cells, block multiple signaling pathways simultaneously, or enhance the efficacy of existing therapies. There are several formats for bispecific antibodies, including T cell engagers, dual-targeting antibodies, and bispecific antibody conjugates.
The research study on the bispecific antibody market overview thoroughly analyzes the market, along with the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth bispecific antibody market forecasts to the industry stakeholders.
Bispecific Antibody Market Dynamics
Bispecific antibodies have shown great promise in cancer treatment, and as the global cancer burden continues to rise, the demand for effective cancer therapies is also increasing. Bispecific antibodies are being developed to treat various cancers, including breast cancer, leukemia, and lymphoma. Immunotherapy is a promising approach for treating various diseases, including cancer and autoimmune disorders. These antibodies are being developed to harness the immune system's power and improve immunotherapy's effectiveness. Additionally, significant advancements in antibody engineering technologies, such as genetic engineering and protein engineering, have enabled the development of bispecific antibodies with improved specificity and efficacy. These advancements are expected to drive the development of more effective bispecific antibodies. Moreover, the growing investment is expected to drive the development and commercialization of new bispecific antibody products. Several blockbuster drugs are set to lose their patent protection in the coming years, leading to a significant increase in the competition in the market. Bispecific antibodies are seen as a promising area for drug development and are expected to help companies maintain their competitive edge in the market.
However, bispecific antibodies are more complex to manufacture than traditional monoclonal antibodies. The production process requires the expression of two different binding domains in a single molecule, which can be challenging and expensive. Bispecific antibodies represent a new class of therapeutics, and there is a lack of regulatory guidance on developing and approving these products. This can lead to delays in the approval process and uncertainty for developers. The bispecific antibody market is highly competitive, and intellectual property challenges are associated with developing and commercializing these products. Patent disputes can lead to delays in the launch of new products and significant legal costs. Designing clinical trials for bispecific antibodies can be challenging, as they often involve complex patient populations and endpoints. There is also a lack of consensus on the best endpoints for bispecific antibody used in clinical trials. The high cost of development and manufacturing for bispecific antibodies can lead to high pricing for patients, which may limit access to these therapies.
Bispecific Antibody Market Ecosystem
Bispecific Antibody Market, by Type
Bispecific Antibody Market, by Drug Type
Bispecific Antibody Market, by Indication
Bispecific Antibody Market by Drug Type
[568]
Blinatumomab drug accounts for a sizeable revenue share in the global bispecific antibody market and is expected to show notable growth during the forecast period from 2023 to 2031. Blinatumomab is one of the immunotherapies known as a bispecific T-cell engager molecule (BiTE). Blinatumomab is an antineoplastic antibody that treats CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. It is FDA-approved for treating adults and children with Philadelphia chromosome-positive and Philadelphia chromosome-negative relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia with minimal residual disease.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as type, drug type, indication, and region. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential market growth opportunities.
Bispecific Antibody Market by Region
North America has a well-established biopharmaceutical industry, with many leading pharmaceutical companies and biotech startups in the region. This has led to significant investment in researching and developing bispecific antibodies in North America. The United States has a robust regulatory framework for drug development and approval, facilitating the development and approval of bispecific antibodies in the region. Additionally, the healthcare system in North America has a favorable reimbursement policy for biologics, including bispecific antibodies. This has created a conducive environment for developing and commercializing bispecific antibodies in the region. North America's well-established venture capital industry has provided significant funding for biotech startups and early-stage companies developing bispecific antibodies. This has helped to accelerate the development and commercialization of these therapies in the region. North America has several leading academic institutions actively engaged in bispecific antibody research. These institutions have contributed significantly to developing new bispecific antibodies and helped create a strong innovation ecosystem in the region.
Based on the regions, the global bispecific antibody market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding bispecific antibody market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
Bispecific Antibody Market Competitive Landscape
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the bispecific antibody industry trends.
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Bispecific antibodies are a class of therapeutics designed to target two antigens simultaneously.
North America accounts for the largest global bispecific antibody market revenue share.
The global bispecific antibody market is estimated to grow at a revenue CAGR of 9.01% from 2023 to 2031
The rising prevalence of cancer cases and growing research activities are prominent trends in global bispecific antibodies.
Rising research and development activities for developing novel products are a few opportunities in the global bispecific antibody market.
The high treatment cost and limited knowledge availability are the major restraining factors that can hamper the overall market growth.
F. Hoffmann-La Roche Ltd, Pfizer Inc., Amgen Inc., Novartis AG, and other notable players are some of the major market players in the global bispecific antibody market.
The blinatumomab drug type segment accounts for the highest revenue share in the global market
Europe accounts for the second-largest bispecific antibody market size during the forecast period from 2023 to 2031
*Insights on financial performance are subject to the availability of information in the public domain